Corpus Intelligence IC Memo — CASCADE VALLEY HOSPITAL 2026-04-26 12:25 UTC
IC Memo — CASCADE VALLEY HOSPITAL
Investment Committee Memorandum | WA | 48 beds | Grade C | EBITDA uplift $5.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

CASCADE VALLEY HOSPITAL

CCN 500060 | SNOHOMISH, WA | 48 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

CASCADE VALLEY HOSPITAL is a 48-bed suburban community hospital in SNOHOMISH, WA with $79.2M in net patient revenue and a 21.3% operating margin. The hospital serves a payer mix of 26.5% Medicare, 1.6% Medicaid, and 71.9% commercial.

Thesis: Turnaround. Our ML models identify $5.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 21.3% to 28.7% (+736bps).

Net Revenue HCRIS$79.2M
Current EBITDA COMPUTED$16.9M
Operating Margin COMPUTED21.3%
Occupancy HCRIS47.9%
Revenue / Bed COMPUTED$1.7M
Net-to-Gross HCRIS29.1%
Distress Probability ML47.0%

2. Market Context & Competitive Position

104
WA Hospitals
-10.3%
State Median Margin
41
Comparable Hospitals

WA has 104 Medicare-certified hospitals with a median operating margin of -10.3%. The target's margin of 21.3% places it above the state median. Among 41 size-comparable peers (24-96 beds), the median margin is -9.3%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (24-96), prioritizing same-state peers. 41 hospitals in the comp set.

HospitalStateBedsRevenueMargin
CASCADE VALLEY HOSPITAL (Target)WA48$79.2M21.3%
OLYMPIC MEDICAL CENTERWA78$237.9M-12.2%
MULTICARE AUBURN MEDICAL CENTEWA84$214.7M-21.1%
PROV ST MARY MEDICAL CENTERWA95$211.5M-11.7%
JEFFERSON GENERAL HOSPITALWA25$148.0M-3.0%
SAMARITAN HOSPITALWA48$137.4M-4.1%
MASON GENERAL HOSPITALWA25$127.1M-5.3%
KITTITAS VALLEY COMMUNITY HOSPWA25$121.0M2.3%
TRI-STATE MEMORIAL HOSPITALWA25$107.0M0.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $5.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.7M+210bp18mo
Cost to Collect4.5%2.5%$1.6M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.6M+198bp12mo
A/R Days Reduction5200.0%3800.0%$964K+122bp9mo
Clean Claim Rate88.0%96.0%$51K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.7M
Cost to Collect
$1.6M
Denial Rate Reduction
$1.6M
A/R Days Reduction
$964K
Clean Claim Rate
$51K
Total EBITDA Uplift$5.8M
Current EBITDA$16.9M
+ RCM Uplift+$5.8M
Pro Forma EBITDA$22.7M
Current Margin21.3%
Pro Forma Margin28.7%
WC Released (1x)$3.0M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$26.0M$169.8M6.53x45.5%
Base (11x exit)10.0x11.0x$26.0M$195.2M7.51x49.7%
Bull Case9.0x11.0x$23.4M$222.9M9.53x57.0%
Bull (12x exit)9.0x12.0x$23.4M$250.1M10.69x60.6%
Bear Case11.0x10.0x$28.6M$132.2M4.62x35.8%
Bear (11x exit)11.0x11.0x$28.6M$154.7M5.41x40.2%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 41 hospitals with 24-96 beds
  • Same-state prioritization (n=42)
  • Comp margins: P25=-14.0% / P50=-9.3% / P75=-3.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.